DNA诊断市场－全球产业规模、份额、趋势、机会及预测（按技术、应用、地区和竞争格局划分，2021-2031年）

全球 DNA 诊断市场预计将从 2025 年的 128.6 亿美元成长到 2031 年的 180.1 亿美元，复合年增长率为 5.77%。

DNA诊断是一种能够精确检测遗传物质，从而发现特定突变、染色体异常或与遗传性感染疾病相关的生物标记的技术。推动该市场发展的关键因素是全球慢性病和感染疾病发病率的上升，这需要快速且准确的检测能力；以及医疗保健策略向个人化医疗的转变。世界卫生组织（世卫组织）在2024年的报告中强调了这项迫切需求：2023年全球约有820万例新增结核病病例，这是自监测开始以来年度新增病例数最高的一年。

然而，由于法规环境复杂多变，进入门槛高，市场成长面临许多挑战。检查室自研检测的严格监管为製造商带来巨大的不确定性和更高的合规成本，可能延缓创新诊断检测的上市。此外，不同司法管辖区报销政策的不一致往往加剧了这些监管压力，限制了患者获得先进基因检测的机会，并限制了相关人员的收入前景。

市场驱动因素

次世代定序技术的快速发展正从根本上改变DNA诊断领域，显着提升了检测通量并缩短了结果交付时间。高通量定序平台的引入使检查室能够以极快的速度和极低的成本处理基因检体，从而推动了其在临床环境中的广泛应用。例如，Illumina公司于2024年2月发布的「2023财年第四季及全年财务业绩」报告显示，该财年共交付了352台NovaSeq X定序仪，充分展现了尖端定序基础设施在市场上的强劲需求。这项技术的广泛应用实现了全面的基因组分析，使得以往难以识别的复杂基因突变得以检测，加速了基因组学在日常医疗保健中的应用。

同时，由于精准医疗和早期疾病检测的重要性，诊断技术在癌症诊断领域的广泛应用成为推动该领域的主要动力。随着全球癌症负担的加重，医疗服务提供者越来越依赖液态生物检体和基因组检测来制定个人化的治疗方案。世界卫生组织（WHO）下属的国际癌症研究机构（IARC）估计，2022年全球新增癌症病例约2,000万例，凸显了诊断需求的巨大规模。因此，专科医疗机构对特异性检测的需求激增。例如，Guardant Health在其2024年2月发布的「2023年第四季及全年业绩报告」中指出，其临床检测量增加了39%，全年为客户提供了172,900次检测。

市场挑战

复杂且不断变化的监管环境对全球DNA诊断市场的发展构成重大障碍。尤其针对检查室自建检测（LDT）和体外诊断试剂的严格监管，显着提高了临床检查室和生产商的进入门槛。这些日益严格的监管要求需要大量的检验程序，迫使企业将大量资源投入合规而非创新。这项变更直接增加了推出新检测方法所需的资金，延长了研发週期，有效延缓了先进诊断工具的商业化进程，并限制了患者获得必要的基因检测的机会。

这些合规障碍带来的财务负担庞大且可量化。根据欧洲医疗技术协会 (MedTech Europe) 2024 年的报告，在新体外诊断医疗设备法规 (IVDR) 下，诊断设备製造商的认证和维修成本将比先前的指令增加高达 100%。营运成本的急剧上升会抑制企业对新检测技术研发的投资，迫使企业重新评估其策略重点，最终阻碍产业的扩张潜力和收入成长。

市场趋势

实验室正日益将人工智慧 (AI) 和机器学习演算法融入其生物资讯学工作流程，以实现数据解读自动化、提高诊断准确性并管理定序产生的大量数据集。这种整合消除了人工突变分析的关键瓶颈，从而能够提供可扩展的临床决策支援并快速识别复杂的遗传疾病。 SOPHiA GENETICS 于 2025 年 3 月发布的「2024 财年第四季及全年」财报印证了这项广泛应用。报告指出，2024 财年，使用其数据驱动平台进行的基因组分析数量达到创纪录的 35.2 万例，较去年同期成长 11%。

同时，技术进步正推动DNA检测的去中心化，将复杂的分子诊断从集中式实验室转移到适用于诊所和偏远地区的携带式快速检测设备。这项转变已将检测结果的周转时间从数天大幅缩短至数分钟，使得感染疾病和急性疾病的治疗决策能够即时做出，而无需庞大的基础设施。生物梅里埃公司于2025年3月发布的2024年财务业绩报告印证了这一市场转变，报告指出，其SPOTFIRE快速照护现场诊断系统2024年的销售额将达到约9500万欧元，且年内新增安装量为2200套。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球DNA诊断市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依技术分类（基于PCR的诊断、次世代定序（NGS）DNA诊断、原位杂合反应诊断、基于微阵列的诊断、其他技术）
  • 依应用领域（癌症基因检测、感染疾病DNA检测、新生儿基因筛检、胚胎胚胎着床前/生殖诊断、非感染疾病DNA检测、新生儿基因筛检、胚胎胚胎着床前/生殖诊断、非感染疾病DNA检测）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美DNA诊断市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

第七章 欧洲DNA诊断市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区DNA诊断市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲DNA诊断市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲DNA诊断市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球DNA诊断市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Illumina, Inc.
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• QIAGEN NV
• Abbott Laboratories
• Bio-Rad Laboratories, Inc.
• Hologic, Inc.
• Agilent Technologies, Inc.
• Siemens Healthineers AG

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global DNA Diagnostics Market is projected to expand from USD 12.86 Billion in 2025 to USD 18.01 Billion by 2031, reflecting a CAGR of 5.77%. DNA diagnostics involve the precise examination of genetic material to detect specific mutations, chromosomal anomalies, or biomarkers linked to hereditary conditions, oncological diseases, and infectious pathologies. This market is primarily driven by the rising global incidence of chronic and infectious diseases, which necessitates rapid and accurate detection capabilities, alongside a strategic healthcare shift toward personalized medicine. Underscoring this urgent need, the World Health Organization reported in 2024 that approximately 8.2 million individuals were newly diagnosed with tuberculosis in 2023, representing the highest annual number of new cases since monitoring began.

However, market growth confronts significant hurdles due to a complex and shifting regulatory environment that establishes high barriers to entry. Strict oversight concerning laboratory-developed tests has created substantial uncertainty and elevated compliance costs for manufacturers, potentially delaying the launch of innovative diagnostic assays. These regulatory pressures are often exacerbated by inconsistent reimbursement policies across various jurisdictions, which limit patient access to advanced genetic testing and constrain the revenue prospects for industry stakeholders.

Market Driver

Rapid technological advancements in Next-Generation Sequencing are fundamentally transforming the DNA diagnostics sector by increasing throughput and shortening turnaround times. The deployment of high-capacity sequencing platforms allows laboratories to process genetic samples with exceptional speed and cost-effectiveness, enabling broader clinical adoption. For instance, Illumina's "Financial Results for Fourth Quarter and Fiscal Year 2023," released in February 2024, noted the shipment of 352 NovaSeq X instruments during the fiscal year, indicating robust market adoption of cutting-edge sequencing infrastructure. This technological proliferation facilitates the availability of comprehensive genomic profiling, permitting the detection of complex genetic variants that were previously challenging to identify, thereby accelerating the integration of genomics into routine medical practice.

Simultaneously, the expanding application of diagnostics in oncology is a major growth engine, driven by the critical need for precision medicine and early disease detection. With the global cancer burden intensifying, healthcare providers are increasingly relying on liquid biopsies and genomic testing to tailor treatment plans. In 2024, the World Health Organization's International Agency for Research on Cancer estimated there were approximately 20 million new cancer cases globally in 2022, highlighting the immense scale of diagnostic requirements. Consequently, specialized providers are seeing a surge in demand for cancer-specific assays; illustrating this, Guardant Health reported in its February 2024 "Fourth Quarter and Full Year 2023 Financial Results" a 39% increase in clinical testing volume, delivering 172,900 tests to customers throughout the year.

Market Challenge

The intricate and evolving regulatory landscape stands as a major impediment to the growth of the Global DNA Diagnostics Market. The enforcement of stringent oversight, particularly regarding Laboratory-Developed Tests (LDTs) and in vitro diagnostics, has created substantial barriers to entry for clinical laboratories and manufacturers. These heightened regulatory requirements necessitate exhaustive validation procedures, compelling companies to divert significant resources toward compliance rather than innovation. This shift directly increases the capital required to introduce new assays and prolongs development timelines, effectively postponing the commercialization of advanced diagnostic tools and restricting patient access to essential genetic testing.

The financial strain resulting from these compliance hurdles is both severe and quantifiable. According to MedTech Europe in 2024, the costs associated with certification and maintenance for diagnostic manufacturers under the new In Vitro Diagnostic Regulation have escalated by up to 100% compared to previous directives. This dramatic rise in operational expenditures discourages investment in new test development and forces companies to reconsider their strategic priorities, ultimately stifling the sector's potential for expansion and revenue growth.

Market Trends

Laboratories are increasingly embedding artificial intelligence and machine learning algorithms into bioinformatics workflows to automate data interpretation, enhance diagnostic accuracy, and manage the massive datasets produced by sequencing. This integration addresses the critical bottleneck of manual variant analysis, allowing for scalable clinical decision support and faster identification of complex genetic conditions. Validating this widespread adoption, SOPHiA GENETICS stated in its March 2025 "Fourth Quarter and Full Year 2024 Results" that the company conducted a record 352,000 genomic analyses using its data-driven platform in fiscal year 2024, representing an 11% year-over-year volume growth.

Technological advancements are simultaneously enabling the decentralization of DNA testing, moving complex molecular diagnostics from centralized laboratories to portable, rapid testing devices suitable for clinics and remote settings. This shift dramatically reduces turnaround times from days to minutes, facilitating immediate treatment decisions for infectious diseases and acute conditions without the need for heavy infrastructure. Underscoring this market evolution, bioMerieux reported in its "2024 Financial Results" in March 2025 that sales of the SPOTFIRE rapid point-of-care molecular system reached nearly €95 million in 2024, with the installed base expanding by 2,200 units during the year.

Key Market Players

• Illumina, Inc.
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Abbott Laboratories
• Bio-Rad Laboratories, Inc.
• Hologic, Inc.
• Agilent Technologies, Inc.
• Siemens Healthineers AG

Report Scope

In this report, the Global DNA Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

DNA Diagnostics Market, By Technology

• PCR-based Diagnostics
• NGS DNA Diagnosis
• In-Situ Hybridization Diagnostics
• Microarrays-based Diagnostics
• Other Technologies

DNA Diagnostics Market, By Application

• Cancer Genetics Tests
• Infectious Diseases DNA Testing
• Newborn Genetic Screening
• Preimplantation & Reproductive Diagnosis
• Non-Infectious Diseases DNA Testing
• Newborn Genetic Screening
• Preimplantation & Reproductive Diagnosis
• Non-Infectious Diseases DNA Testing

DNA Diagnostics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global DNA Diagnostics Market.

Available Customizations:

Global DNA Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global DNA Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (PCR-based Diagnostics, NGS DNA Diagnosis, In-Situ Hybridization Diagnostics, Microarrays-based Diagnostics, Other Technologies)
  • 5.2.2. By Application (Cancer Genetics Tests, Infectious Diseases DNA Testing, Newborn Genetic Screening, Preimplantation & Reproductive Diagnosis, Non-Infectious Diseases DNA Testing, Newborn Genetic Screening, Preimplantation & Reproductive Diagnosis, Non-Infectious Diseases DNA Testing)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America DNA Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States DNA Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada DNA Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico DNA Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Application

7. Europe DNA Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany DNA Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Application
  • 7.3.2. France DNA Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom DNA Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy DNA Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain DNA Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Application

8. Asia Pacific DNA Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China DNA Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Application
  • 8.3.2. India DNA Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan DNA Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea DNA Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia DNA Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Application

9. Middle East & Africa DNA Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia DNA Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE DNA Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa DNA Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Application

10. South America DNA Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil DNA Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia DNA Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina DNA Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global DNA Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Illumina, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Danaher Corporation
• 15.3. F. Hoffmann-La Roche Ltd.
• 15.4. Thermo Fisher Scientific Inc.
• 15.5. QIAGEN N.V.
• 15.6. Abbott Laboratories
• 15.7. Bio-Rad Laboratories, Inc.
• 15.8. Hologic, Inc.
• 15.9. Agilent Technologies, Inc.
• 15.10. Siemens Healthineers AG

16. Strategic Recommendations

17. About Us & Disclaimer